[go: up one dir, main page]

ES2151593T3 - Androstanos y pregnanos para modulacion alosterica del receptor de gaba. - Google Patents

Androstanos y pregnanos para modulacion alosterica del receptor de gaba.

Info

Publication number
ES2151593T3
ES2151593T3 ES95913478T ES95913478T ES2151593T3 ES 2151593 T3 ES2151593 T3 ES 2151593T3 ES 95913478 T ES95913478 T ES 95913478T ES 95913478 T ES95913478 T ES 95913478T ES 2151593 T3 ES2151593 T3 ES 2151593T3
Authority
ES
Spain
Prior art keywords
gaba
androstans
pregnans
receiver
allosteric modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913478T
Other languages
English (en)
Inventor
Ravindra B Upasani
Haiji Xia
Derk Hogenkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26892391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2151593(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Application granted granted Critical
Publication of ES2151593T3 publication Critical patent/ES2151593T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Polymerisation Methods In General (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

METODOS, COMPOSICIONES Y COMPUESTOS PARA LA MODULACION DEL COMPLEJO IONOFORO DEL RECEPTOR DE CLORURO GABA{SUB,A} PARA ALIVIAR EL STRESS, LA ANSIEDAD, ATAQUES, TRASTORNOS DEL COMPORTAMIENTO, PMS Y PND Y PARA FACILITAR LA ANESTESIA.
ES95913478T 1994-02-14 1995-02-14 Androstanos y pregnanos para modulacion alosterica del receptor de gaba. Expired - Lifetime ES2151593T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19691994A 1994-02-14 1994-02-14
US34692794A 1994-11-23 1994-11-23

Publications (1)

Publication Number Publication Date
ES2151593T3 true ES2151593T3 (es) 2001-01-01

Family

ID=26892391

Family Applications (2)

Application Number Title Priority Date Filing Date
ES00200119T Expired - Lifetime ES2296594T3 (es) 1994-02-14 1995-02-14 Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
ES95913478T Expired - Lifetime ES2151593T3 (es) 1994-02-14 1995-02-14 Androstanos y pregnanos para modulacion alosterica del receptor de gaba.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES00200119T Expired - Lifetime ES2296594T3 (es) 1994-02-14 1995-02-14 Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.

Country Status (17)

Country Link
EP (2) EP1038880B1 (es)
JP (1) JP4066272B2 (es)
KR (1) KR100338287B1 (es)
AT (2) ATE195654T1 (es)
AU (1) AU691905B2 (es)
BR (1) BR9506779A (es)
CA (1) CA2183231A1 (es)
DE (2) DE69535623T2 (es)
DK (2) DK1038880T3 (es)
ES (2) ES2296594T3 (es)
FI (2) FI118008B (es)
GR (1) GR3034810T3 (es)
IL (1) IL112638A (es)
NO (1) NO308307B1 (es)
NZ (1) NZ282939A (es)
PT (2) PT1038880E (es)
WO (1) WO1995021617A1 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
CA2223996A1 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series
US20010051599A1 (en) 1997-05-02 2001-12-13 Michael Z. Kagan Pregnan-3-ol-20-ones
EP1449846A1 (en) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
HUP0201818A3 (en) * 1999-04-29 2004-04-28 Euro Celtique Sa 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
EP1228083A2 (en) 1999-09-30 2002-08-07 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
US7078057B2 (en) 1999-12-20 2006-07-18 Kerkhof Nicholas J Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
DE602006013622D1 (de) * 2005-06-09 2010-05-27 Euro Celtique Sa Steroids und anwendungen davon
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
RU2469042C2 (ru) * 2006-09-19 2012-12-10 Зольвай Фармасьютиклз Гмбх Терапевтически активные триазолы и их использование
ES2662500T3 (es) * 2006-11-21 2018-04-06 Asarina Pharma Ab El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central
CA2698172C (en) * 2007-06-15 2014-02-18 Cook, Kevin M. Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
WO2013036835A1 (en) 2011-09-08 2013-03-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
CN102702126B (zh) * 2012-04-26 2014-08-06 四川大学华西医院 一种可用于麻醉剂的化合物
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
JP2016501876A (ja) 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
HRP20210610T1 (hr) 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) * 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
SG10201803812TA (en) * 2014-05-29 2018-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10172870B2 (en) 2014-09-02 2019-01-08 The Texas A&M University System Method of treating organophosphate intoxication by administration of neurosteroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4275748A3 (en) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3885352B1 (en) * 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6882996B2 (ja) 2015-07-06 2021-06-02 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
SMT202100476T1 (it) 2015-07-06 2021-09-14 Sage Therapeutics Inc Ossisteroli e metodi di uso degli stessi
BR112018000129B1 (pt) 2015-07-06 2024-01-09 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
CN113616661A (zh) 2016-03-08 2021-11-09 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
SI3436022T1 (sl) 2016-04-01 2022-08-31 Sage Therapeutics, Inc. Oksisteroli in postopki za uporabo le-teh
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MX392270B (es) 2016-09-30 2025-03-24 Sage Therapeutics Inc Oxisteroles sustituidos en c7 y metodos de uso de los mismos.
EP4105223B1 (en) 2016-10-18 2025-04-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN110267966B (zh) 2016-10-18 2022-07-08 萨奇治疗股份有限公司 氧甾醇及其使用方法
TW202014192A (zh) * 2018-05-04 2020-04-16 加拿大商阿爾宙斯製藥有限公司 神經類固醇衍生物及其用途
EP4321519A3 (en) * 2018-10-12 2024-05-01 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
KR20210105934A (ko) 2018-12-17 2021-08-27 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
KR102821994B1 (ko) * 2019-01-08 2025-06-19 쳉두 캉홍 파마슈티칼 코., 엘티디. 스테로이드 화합물, 및 이의 용도와 제조방법
CN111410673A (zh) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CA3124703C (en) * 2019-01-14 2023-10-17 Beijing Xuanyi Pharmasciences Co., Ltd. Tetrazolone substituted steroids and use thereof
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
KR102890254B1 (ko) 2019-08-07 2025-11-24 상하이 한서 바이오메디컬 컴퍼니 리미티드 스테로이드 유도체 조절제의 염 및 결정형
CN112341511A (zh) * 2019-08-09 2021-02-09 南京诺瑞特医药科技有限公司 3-羟基-5-孕烷-20-酮衍生物及其用途
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2021174205A1 (en) * 2020-02-27 2021-09-02 Brii Biosciences, Inc. Prodrugs of neuroactive steroids
EP4200312A4 (en) * 2020-08-20 2024-09-25 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274179A (en) * 1964-03-19 1966-09-20 Merck & Co Inc 3-haloethynyl-3-hydroxy derivatives of the androstane-17-one and pregnane-20-one series
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物

Also Published As

Publication number Publication date
EP1038880A2 (en) 2000-09-27
DK1038880T3 (da) 2008-03-03
DE69535623D1 (de) 2007-11-29
DE69518509T2 (de) 2001-04-19
EP0752860A4 (en) 1998-05-06
PT752860E (pt) 2000-12-29
HK1014665A1 (en) 1999-09-30
IL112638A (en) 2003-10-31
NO308307B1 (no) 2000-08-28
FI20051271L (fi) 2005-12-09
GR3034810T3 (en) 2001-02-28
PT1038880E (pt) 2008-01-29
AU2090195A (en) 1995-08-29
AU691905B2 (en) 1998-05-28
EP0752860A1 (en) 1997-01-15
CA2183231A1 (en) 1995-08-17
DK0752860T3 (da) 2000-11-13
JPH09510701A (ja) 1997-10-28
WO1995021617A1 (en) 1995-08-17
DE69535623T2 (de) 2008-07-24
KR100338287B1 (ko) 2002-11-30
FI118687B (fi) 2008-02-15
EP0752860B1 (en) 2000-08-23
NZ282939A (en) 1998-08-26
FI963174A0 (fi) 1996-08-13
BR9506779A (pt) 1997-10-14
JP4066272B2 (ja) 2008-03-26
FI118008B (fi) 2007-05-31
FI963174L (fi) 1996-09-25
NO963355D0 (no) 1996-08-12
DE69518509D1 (de) 2000-09-28
IL112638A0 (en) 1995-05-26
ATE195654T1 (de) 2000-09-15
ATE375993T1 (de) 2007-11-15
EP1038880A3 (en) 2003-07-16
NO963355L (no) 1996-10-11
ES2296594T3 (es) 2008-05-01
EP1038880B1 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
ES2151593T3 (es) Androstanos y pregnanos para modulacion alosterica del receptor de gaba.
ATE411290T1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
DK0804236T3 (da) Anvendelse af anti-TNF-antistoffer som lægemidler til behandling af sygdomme, som involverer forhøjede interleukin-6-serumniveauer
TR199701146T1 (xx) N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler.
ATE291429T1 (de) Mittel gegen juckreiz
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
ES2155543T3 (es) Serie de androstano y pregnano para modulacion alosterica del receptor de gaba.
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
DE602004028286D1 (de) Verwendung von sphingosin-1-phosphat (s1p) rezeptor-agonisten zur behandlung von degenerativen gehirnerkrankungen
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
ECSP066268A (es) Inhibidores de la miostatina (gdf8) en combinación con corticoesteroides para el tratamiento de desórdenes neuromusculares
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
DE69931957D1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns-erkrankungen
ATE440827T1 (de) Melanocortin-rezeptormodulatoren
DE60044152D1 (de) Bupropion Metaboliten zur Behandlung von Angstzuständen
DK1091745T3 (da) Behandling af hyperproliferative forstyrrelser
TR200200408T2 (tr) Yeni spiro bileşikleri
NO20000521L (no) 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 põ fenylringen
DE602004027251D1 (de) Herstellung von 1,3-diphenylprop-2-en-1-onderivaten
EA200501868A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
NO20014240L (no) C16-umettede FP-selektive prostaglandinanaloger
DK1305037T3 (da) Smertestillende medikament
ECSP003590A (es) Compuestos calcioliticos
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752860

Country of ref document: ES